| Authors: |
Naing A; Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, Texas, USA anaing@mdanderson.org., Powderly JD; Cancer Research Clinic, Carolina Biooncology Institute, Huntersville, North Carolina, USA., Nemunaitis JJ; University of Toledo College of Medicine, Toledo, Ohio, USA., Luke JJ; Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Mansfield AS; Oncology, Mayo Clinic, Rochester, Minnesota, USA., Messersmith WA; School of Medicine, University of Colorado, Aurora, Colorado, USA., Sahebjam S; Clinical Research Unit, Moffitt Cancer Center, Tampa, Florida, USA., LoRusso PM; Yale School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA., Garrido-Laguna I; University of Utah School of Medicine, Huntsman Cancer Institute, Salt Lake City, Utah, USA., Leopold L; Immuno-Oncology, Incyte Corporation, Wilmington, Delaware, USA., Geschwindt R; Immuno-Oncology, Incyte Corporation, Wilmington, Delaware, USA., Ding K; Biostatistics, Incyte Corporation, Wilmington, Delaware, USA., Smith M; Immuno-Oncology, Incyte Corporation, Wilmington, Delaware, USA., Berlin JD; Division of Hematology/Oncology, Vanderbilt University, Nashville, Tennessee, USA. |
